SEC Form 4 · accession 0001209191-16-133688

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jul 20, 2016

Accepted (ET)

Jul 22, 2016 · 2:11 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jul 20, 2016	M	6,500	$36.30	A	274,725	D
Common Stock^F2,F3	Jul 20, 2016	S	300	$87.69	D	274,425	D
Common Stock^F2,F4	Jul 20, 2016	S	600	$88.92	D	273,825	D
Common Stock^F2,F5	Jul 20, 2016	S	2,600	$90.28	D	271,225	D
Common Stock^F2,F6	Jul 20, 2016	S	3,000	$90.91	D	268,225	D
Common Stock	holding	—	—		—	13,286	I	401k
Common Stock	holding	—	—		—	122,700	I	Common Stock Held In Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F7	$36.30	Jul 20, 2016	M	6,500	D	—	Jan 23, 2017	Common Stock	6,500	164,000	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $87.69 (range $87.17 to $88.06).
F4Open market sales reported on this line occurred at a weighted average price of $88.92 (range $88.42 to $89.30).
F5Open market sales reported on this line occurred at a weighted average price of $90.28 (range $89.62 to $90.61).
F6Open market sales reported on this line occurred at a weighted average price of $90.91 (range $90.62 to $91.19).
F7Fully vested.